MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Y-mAbs Therapeutics Long Term Debt Current 2011-2026 | YMAB
Annual Long Term Debt Current Y-mAbs Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 630 K | 902 K | 868 K | 1.78 M | 1.97 M | 516 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.97 M | 516 K | 1.11 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
5.82 M | $ 3.54 | -0.56 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
1.03 M | $ 3.2 | 2.24 % | $ 229 M |  Schweiz |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
ADC Therapeutics SA
ADCT
|
1.1 M | $ 4.17 | -1.18 % | $ 105 M | Schweiz |
 |
Aptorum Group Limited
APM
|
433 K | $ 0.8 | 1.81 % | $ 4.36 M | China |
 |
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 6.55 | -1.21 % | $ 179 M |  Israel |
 |
argenx SE
ARGX
|
6.53 M | $ 710.47 | 1.02 % | $ 25 B |  Niderland |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.41 | -5.54 % | $ 8.2 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 229.89 | -0.49 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
BioCardia
BCDA
|
333 K | $ 1.28 | 0.55 % | $ 27.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
843 K | $ 6.12 | 1.16 % | $ 499 M | USA |
 |
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.51 | -2.23 % | $ 7.64 B | Israel |
 |
Catalyst Biosciences
CBIO
|
636 K | $ 11.32 | -2.25 % | $ 1.01 B | USA |
 |
Anika Therapeutics
ANIK
|
1.6 M | $ 14.64 | 1.92 % | $ 215 M | USA |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
428 K | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
11 K | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.64 | - | $ 16.6 M | USA |
 |
Curis
CRIS
|
1.34 M | $ 0.88 | 2.58 % | $ 5.55 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.51 | - | $ 385 M |  Britain |
 |
BioNTech SE
BNTX
|
45 M | $ 92.24 | 1.88 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
414 K | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |